- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Cetificate
- 31.2 CFO 302 Cetificate
- 32 906 Cetificate
- PDF 10-K
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Cetificate
- 31.2 CFO 302 Cetificate
- 32 906 Cetificate
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NPS Pharmaceuticals, Inc.:
We consent to incorporation by reference in the registration statements (Nos. 33-79622, 333-17521, 333-94269, 333-124821, 333-126823, 333-159363, and 333-168533) on Form S-8 and (Nos. 333-146235, 333-159321, 333-169388, and 333-170283) on Form S-3 of NPS Pharmaceuticals, Inc. of our reports dated February 15, 2011, with respect to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2010 and 2009, and the related consolidated statements of operations, stockholders' deficit and comprehensive loss, and cash flows for each of the years in the three-year period ended December 31, 2010, and the effectiveness of internal control over financial reporting as of December 31, 2010, which reports appear in the December 31, 2010 annual report on Form 10-K of NPS Pharmaceuticals, Inc.
/s/ KPMG LLP
Princeton, New Jersey
February 15, 2011